

42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

ROBERT A. BRADWAY, CHAIRMAN AND CHIEF EXECUTIVE OFFICER

January 8, 2024

AMGEN




SAFE HARBOR STATEMENT


This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this presentation and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

WE ARE ADDRESSING AN ARRAY OF SERIOUS DISEASES...



...WITH A NUMBER OF NOVEL MEDICINES



2023: ANOTHER YEAR OF PERFORMANCE AND PROGRESS

- ✓ **Delivered double-digit volume growth across products and geographies**
- ✓ **Advanced a broad and deep pipeline**
- ✓ **Created Rare Disease business to include Horizon and TAVNEOS®**
- ✓ **Advanced our biosimilars portfolio**
- ✓ **Continued our track record of uninterrupted supply and manufacturing excellence**
- ✓ **Delivered attractive financial returns**
- ✓ **Positioned to accelerate innovation through convergence of biotech and tech**

FOUR PILLARS DRIVING LONG-TERM GROWTH


GENERAL
MEDICINE



ONCOLOGY



INFLAMMATION



RARE DISEASE



Marketed Products
Innovative Pipeline
Biosimilars



OUR FIRST-IN-CLASS MEDICINES ARE DRIVING VOLUME GROWTH ACROSS PRODUCTS AND GEOGRAPHIES



GENERAL MEDICINE: KEY MARKETED PRODUCTS

 **Repatha**
(evolocumab) injection
140 mg/mL

- **One out of three deaths worldwide are due to cardiovascular disease¹**

- Repatha® is global PCSK9 market leader with broad access

 **EVENITY**[™]
(romosozumab-aqqg)
injection 105 mg/117 mL

- **More than 200 million people worldwide suffer from osteoporosis²**

- Prolia® and EVENITY® are stronger together in reducing osteoporotic fractures

 **prolia**[®]
(denosumab) injection

Sources: 1. World Health Organization. Cardiovascular Diseases (CVDs) Fact Sheet. [https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)). Accessed January 2, 2023. 2. Register JY, Burlet N. Osteoporosis: A still increasing prevalence. Bone. 2006;38 (2 Suppl 1):S4-S9. PCSK9 = proprotein convertase subtilisin/kexin type 9.

7 Provided January 8, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

AMGEN

PIPELINE FOCUSED ON POTENTIALLY BEST-IN-CLASS THERAPIES IN LARGE PATIENT POPULATIONS



GENERAL MEDICINE: SELECTED PIPELINE PROGRAMS

Obesity and Related Comorbidities

- MariTide (maridebart cafraglutide) in Phase 2 with potential for differentiated profile
- AMG 786 oral small molecule in Phase 1
- Additional preclinical programs

Cardiovascular Disease

- Repatha® Phase 3 primary prevention trial in high-risk cardiovascular patients
- Olpasiran rapidly enrolling Phase 3 in cardiovascular patients with high levels of Lp(a)

Lp(a) = lipoprotein (a).

BROAD PORTFOLIO PROVIDES IMPORTANT TREATMENT OPTIONS FOR PATIENTS AND PROVIDERS



ONCOLOGY: KEY MARKETED PRODUCTS



- Strong commercial execution driving double-digit growth in 2023
- BLINCYTO[®] and Vectibix[®] achieved record quarterly sales in Q3 2023
- Kyprolis[®], Nplate[®], and XGEVA[®] each at blockbuster levels in 2023

1 IN 5 CANCER PATIENTS RECEIVES AN AMGEN MEDICINE

PIPELINE FOCUSED ON HIGH-CONVICTION TARGETS, DIFFERENTIATED THERAPIES, AND LARGE EFFECT SIZE



ONCOLOGY: SELECTED PIPELINE PROGRAMS

- **Tarlatamab** priority regulatory review underway in advanced small cell lung cancer
- **BLINCYTO**[®] moving into frontline¹ B-ALL treatment and developing subcutaneous administration
- **Xaluritamig** rapidly enrolling Phase 1 dose expansion in prostate cancer
- **AMG 193** responses across seven tumor types in Phase 1
- **LUMAKRAS**[®] advancing Phase 3 studies in first-line non-small cell lung cancer and first-line colorectal cancer
- **Bemarituzumab** rapidly enrolling Phase 3 in first-line gastric cancer

B-ALL = B-cell precursor acute lymphoblastic leukemia.


Xaluritamig, formerly AMG 509, is being developed pursuant to a research collaboration with Xencor, Inc..

1. Frontline consolidation for adult and adolescent / young adult B-ALL patients, regardless of minimal residual disease status, age, or Philadelphia-chromosome status as well as ECOG 1910 as a frontline regimen.

TARLATAMAB: A POTENTIAL BREAKTHROUGH IN ADVANCED SMALL CELL LUNG CANCER



ONCOLOGY: SELECTED PIPELINE PROGRAMS



- PDUFA date of June 12, 2024
- Response rate of 40%, with 6-month survival of 73% in advanced small cell lung cancer
- Initiating Phase 3 trials in earlier lines
- First T-cell engager to demonstrate activity in a common solid tumor


U.S. DRUG-TREATED POPULATION OF ~35K ACROSS ALL LINES OF DISEASE

DLL3 - delta-like ligand 3; CD3 = cluster of differentiation 3; Fc = fragment crystallizable; SCLC = small cell lung cancer; PDUFA = Prescription Drug User Fee Act.

11 Provided January 8, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

AMGEN

INNOVATIVE MEDICINES PROVIDE STRONG FOUNDATION FOR GROWTH



INFLAMMATION: KEY MARKETED PRODUCTS



- **TEZSPIRE® recently launched and is first-in-class novel therapy**
 - Serious asthma exacerbations require 1.6M emergency room visits per year in the U.S. alone¹



- **Expect Otezla® growth driven by differentiated profile and increased investment**




- **> 20 years of leadership in inflammation**

Sources: 1. Nunes C, et al. Asthma Res Pract. 2017;3:2-11.
TEZSPIRE® is being developed in collaboration with AstraZeneca.

12 Provided January 8, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.



PIPELINE FOCUSED ON DIFFICULT-TO-TREAT DISEASES WITH HIGH UNMET NEED



INFLAMMATION: SELECTED PIPELINE PROGRAMS

TEZSPIRE®: pursuing additional indications

- Chronic rhinosinusitis with nasal polyps Phase 3
- Eosinophilic esophagitis Phase 3
- Chronic obstructive pulmonary disease Phase 2

Rocatinlimab: potentially first-in-class atopic dermatitis therapy

- Over 2,000 patients enrolled in seven-study ROCKET Phase 3 program
- Initial ROCKET Phase 3 data readout this year
- Planning to initiate Phase 2 in asthma

TEZSPIRE® is being developed in collaboration with AstraZeneca. Rocatinlimab, formerly AMG 451/KHK4083, is being developed in collaboration with Kyowa Kirin.

13 Provided January 8, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.



RARE DISEASE BUSINESS CREATES FOURTH PILLAR OF LONG-TERM GROWTH



RARE DISEASE: KEY MARKETED PRODUCTS

TEPEZZA
teprotumumab-trbw

- **First and only thyroid eye disease treatment**

KRYSTEXXA
pegloticase

- **First and only uncontrolled gout treatment**

UPLIZNA
inebilizumab-cdon

- **Fastest-growing biologic in neuromyelitis optica spectrum disorder**

TAVNEOS
(avacopan)

- **Only complement inhibitor for ANCA-associated vasculitis**

ANCA = antineutrophil cytoplasmic antibody.

14 Provided January 8, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.



MULTIPLE PIPELINE PROGRAMS TO DRIVE ADDITIONAL GROWTH



RARE DISEASE: SELECTED PIPELINE PROGRAMS

- **TEPEZZA**[®] enrolling Phase 3 in Japan for chronic/low clinical activity score thyroid eye disease. Advancing subcutaneous administration.
- **UPLIZNA**[®] expecting Phase 3 data in myasthenia gravis and IgG4-related disease
- **Dazodalibep** initiated Phase 3 for Sjogren's syndrome
- **Daxdilimab** pursuing Phase 2 for discoid lupus erythematosus and dermatomyositis and anti-synthetase inflammatory myositis
- **AMG 670 (formerly HZN 825)** conducting Phase 2 in idiopathic pulmonary fibrosis and diffuse cutaneous systemic sclerosis

IgG4 = Immunoglobulin G4.

15 Provided January 8, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.



IMPORTANT PIPELINE MILESTONES ANTICIPATED IN 2024



GENERAL MEDICINE

- **MariTide**
 - Phase 2 obesity data
- **Olpasiran**
 - Complete Phase 3 enrollment
- **AMG 786**
 - Phase 1 obesity data



ONCOLOGY

- **Tarlatamab**
 - PDUFA (June)
 - Initiate additional Phase 3 studies
- **BLINCYTO®**
 - Phase 3 early-stage B-ALL submission
 - Initiate Phase 3 subcutaneous administration study
- **LUMAKRAS®**
 - Phase 3 third-line CRC U.S. submission
 - Initiate Phase 3 in first-line CRC
- **Nplate®**
 - Phase 3 chemo-induced thrombocytopenia data



INFLAMMATION

- **TEZSPIRE®**
 - Phase 2 COPD data
 - Phase 3 chronic rhinosinusitis with nasal polyps data
- **Rocatinlimab**
 - Phase 3 HORIZON study data



RARE DISEASE

- **TEPEZZA®**
 - Japan submission
 - Initiate Phase 3 subcutaneous administration study
- **UPLIZNA®**
 - Phase 3 myasthenia gravis data
 - Phase 3 IgG4-related disease data
- **AMG 670** (formerly HZN 825)
 - Phase 2 idiopathic pulmonary fibrosis data

PDUFA = Prescription Drug User Fee Act; B-ALL = B-cell precursor acute lymphoblastic leukemia; CRC = colorectal cancer; COPD = chronic obstructive pulmonary disease; IgG4 = Immunoglobulin G4. Xaluritamig, formerly AMG 509, is being developed pursuant to a research collaboration with Xencor, Inc.. TEZSPIRE® is being developed in collaboration with AstraZeneca. Rocatinlimab, formerly AMG 451/KHK4083, is being developed in collaboration with Kyowa Kirin.

16 Provided January 8, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.



BIOSIMILARS PORTFOLIO HAS ACHIEVED BLOCKBUSTER RESULTS AND WILL GROW WITH NEW LAUNCHES



ONCOLOGY



MVASI
(bevacizumab-awwb)
Injection 100mg/Vial & 400mg/Vial



INFLAMMATION



AMJEVITA
(adalimumab-atto)
Injection 40mg/20 mL & 20mg/10 mL



RARE DISEASE



BEKEMV
(ecclizumab)



KANJINTI
(trastuzumab-anns)
For Injection 420mg/Vial, multiple uses



AVSOLA
(infliximab-axxq)
For Injection 100mg/Vial



RIABNI
(rituximab-arrx)
Injection 100mg/Vial & 500mg/Vial

- **Global leader in biosimilars**

- Leading in the five markets that comprise > 80% of total global revenue

- **Advancing next wave of opportunities**

- Next three launches: Stelara[®], Soliris[®], Eylea[®]
- ABP 206, an investigational biosimilar to OPDIVO[®]
- Two additional undisclosed opportunities

STELARA is a registered trademark of Janssen Biotech, Inc.; EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.; SOLIRIS is a registered trademark of Alexion Pharmaceuticals, Inc.; OPDIVO is a registered trademark of Bristol-Myers Squibb Company.

17 Provided January 8, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

AMGEN

CONVERGENCE OF BIOTECHNOLOGY AND TECHNOLOGY WILL UNLEASH THE NEXT WAVE OF INNOVATION

- **Positioned at the forefront of the new opportunity**
- **Investing in artificial intelligence across the enterprise**
- **Advancing our world-class human data efforts**
- **Our generative biology platform and multispecific strategy are delivering transformational impact**

OUR RESEARCH AND INNOVATION POSITION US FOR GROWTH BEYOND THIS DECADE

COMMITTED TO GOOD CORPORATE CITIZENSHIP

- Tracking toward carbon neutrality in our operations by 2027
- Investing in the next generation of innovators through the Amgen Foundation
- Working to strengthen healthcare systems in low- and middle- income countries



SUCCESSFULLY IMPLEMENTING OUR STRATEGY TO DELIVER LONG-TERM GROWTH

- **Driving volume growth with our existing innovative products, balanced across our four therapeutic areas and three regions**
- **Rare Disease business provides growth that is additive to our plan**
- **Unprecedented pipeline innovation and breadth**
- **Motivated staff in a strong patient-focused culture**

DRIVING INNOVATION AT SPEED AND SCALE

APPENDIX

AMGEN



IMPORTANT PIPELINE MILESTONES ANTICIPATED IN 2024



GENERAL MEDICINE

- **Maritide** Phase 2 data readout late 2024
- **AMG 786** Phase 1 data readout H1 2024
- **Olpasiran** Phase 3 enrollment completion H1 2024



ONCOLOGY

- **Tarlatamab** PDUFA date of 6/12/24
- **Tarlatamab** additional Phase 3 studies in 1L ES-SCLC and LS-SCLC to be initiated H1 2024
- **BLINCYTO**[®] global regulatory submissions for Phase 3 early-stage B-ALL H1 2024
- **BLINCYTO**[®] Phase 3 subcutaneous administration study in B-ALL initiation H2 2024
- **LUMAKRAS**[®] Phase 3 third-line CRC U.S. submission in H1 2024
- **LUMAKRAS**[®] Phase 3 study in first-line CRC initiation H1 2024
- **Nplate**[®] Phase 3 chemotherapy-induced thrombocytopenia in GI malignancies data readout H2 2024



INFLAMMATION

- **TEZSPIRE**[®] Phase 2 COPD data readout H1 2024
- **TEZSPIRE**[®] chronic rhinosinusitis with nasal polyps Phase 3 primary analysis H2 2024
- **Rocatinlimab** Phase 3 HORIZON study data readout H2 2024



RARE DISEASE

- **TEPEZZA**[®] Japan submission anticipated H1 2024
- **TEPEZZA**[®] Phase 3 study in TED subcutaneous administration initiation H1 2024
- **UPLIZNA**[®] Phase 3 myasthenia gravis data readout H2 2024
- **UPLIZNA**[®] Phase 3 IgG4-related disease data readout H2 2024
- **AMG 670** (formerly HZN 825) Phase 2 IPF data readout H2 2024

PDUFA = Prescription Drug User Fee Act; ES = extensive stage; SCLC = small cell lung cancer; LS = limited stage; B-ALL = B-cell precursor acute lymphoblastic leukemia; CRC = colorectal cancer; GI = gastrointestinal; COPD = chronic obstructive pulmonary disease; TED = thyroid eye disease; IgG4 = Immunoglobulin G4; IPF = idiopathic pulmonary fibrosis.

Xaluritamig, formerly AMG 509, is being developed pursuant to a research collaboration with Xencor, Inc.. TEZSPIRE[®] is being developed in collaboration with AstraZeneca. Rocatinlimab, formerly AMG 451/KHK4083, is being developed in collaboration with Kyowa Kirin.

22 Provided January 8, 2024, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.



42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

ROBERT A. BRADWAY, CHAIRMAN AND CHIEF EXECUTIVE OFFICER

January 8, 2024

AMGEN

